Ectoine enhances recombinant antibody production in Chinese hamster ovary cells by promoting cell cycle arrest
Issued Date
2024-11-25
Resource Type
ISSN
18716784
eISSN
18764347
Scopus ID
2-s2.0-85197423195
Journal Title
New Biotechnology
Volume
83
Start Page
56
End Page
65
Rights Holder(s)
SCOPUS
Bibliographic Citation
New Biotechnology Vol.83 (2024) , 56-65
Suggested Citation
Jarusintanakorn S., Mastrobattista E., Yamabhai M. Ectoine enhances recombinant antibody production in Chinese hamster ovary cells by promoting cell cycle arrest. New Biotechnology Vol.83 (2024) , 56-65. 65. doi:10.1016/j.nbt.2024.06.006 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/99607
Title
Ectoine enhances recombinant antibody production in Chinese hamster ovary cells by promoting cell cycle arrest
Author(s)
Corresponding Author(s)
Other Contributor(s)
Abstract
Chinese hamster ovary (CHO) cells represent the most preferential host cell system for therapeutic monoclonal antibody (mAb) production. Enhancing mAb production in CHO cells can be achieved by adding chemical compounds that regulate the cell cycle and cell survival pathways. This study investigated the impact of ectoine supplementation on mAb production in CHO cells. The results showed that adding ectoine at a concentration of 100 mM on the 3rd day of cultivation improved mAb production by improving cell viability and extending the culture duration. RNA sequencing analysis revealed differentially expressed genes associated with cell cycle regulation, cell proliferation, and cellular homeostasis, in particular promotion of cell cycle arrest, which was then confirmed by flow cytometry analysis. Ectoine-treated CHO cells exhibited an increase in the number of cells in the G0/G1 phase. In addition, the cell diameter was also increased. These findings support the hypothesis that ectoine enhances mAb production in CHO cells through mechanisms involving cell cycle arrest and cellular homeostasis. Overall, this study highlights the potential of ectoine as a promising supplementation strategy to enhance mAb production not only in CHO cells but also in other cell lines.